Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw to Scientific Advisory Board

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Company’s Scientific Advisory Board.

20210216 – HBP Press Release – Dr Renshaw Appointment